+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

ProPhase Labs

(NASDAQ:PRPH)

Intraday

$4.74

-0.65[-12.06%]

After-Hours

$4.74

0[0.00%]

Perks Buy Compare Brokers

$4.74

-0.65[-12.06%]

At close: May 1

$4.74

0[0.00%]

After Hours: 8:05AM EDT

Q1 2024 earnings were released today before the market open

Today's conference call ended over 12 hours ago Click to view the webcast

Overview News Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest News for ProPhase Labs Stock (NASDAQ:PRPH)

ProPhase Labs Stock (NASDAQ: PRPH)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Thursday, May 09, 2024

ProPhase Labs Q1 2024 GAAP EPS $(0.07) Beats $(0.18) Estimate, Sales $3.634M Miss $9.860M Estimate
Benzinga Newsdesk - 11 hours ago

Tuesday, April 16, 2024

ProPhase Labs Unveils Project ZenQ-AI; Leveraging ProPhase Labs' AI Platform, Massive Genomics Database And Patented Esophageal Cancer Insights For Antibody Drug Conjugates Development
Benzinga Newsdesk - Apr 16, 2024, 8:15AM

Wednesday, April 10, 2024

ProPhase Labs Seeks To Transform Esophageal Cancer Detection And Management With Launch Of Its BE-Smart Test In H2 2024
Benzinga Newsdesk - Apr 10, 2024, 8:09AM

Friday, March 15, 2024

ProPhase Labs Q4 EPS $(0.51) Misses $(0.26) Estimate, Sales $4.35M Miss $10.69M Estimate
Benzinga Newsdesk - Mar 15, 2024, 8:10AM
Earnings Scheduled For March 15, 2024
Benzinga Insights - Mar 15, 2024, 5:15AM

Thursday, March 14, 2024

ProPhase Labs's Earnings: A Preview
Benzinga Insights - Mar 14, 2024, 11:00AM

Wednesday, February 21, 2024

HC Wainwright & Co. Reiterates Buy on ProPhase Labs, Maintains $11 Price Target
Benzinga Newsdesk - Feb 21, 2024, 1:20PM

Tuesday, February 20, 2024

ProPhase Labs Announces Progress In BE-Smart Esophageal Cancer Test Development USPTO Grants Additional Broad Patents For BE-SMART
Happy Mohamed - Feb 20, 2024, 8:19AM

Wednesday, February 14, 2024

ProPhase Labs Announces Preliminary Results For Dietary Supplement Equivir, Co. Says Prelim Results Indicate It 'has the potential to support and maintain immunity'
Benzinga Newsdesk - Feb 14, 2024, 8:11AM

Tuesday, January 23, 2024

ProPhase Labs Announces Progress At Pharmaloz Manufacturing Accelerating Expansion, Improves Pricing, Boosts Profitability And Secures New Contracts
Benzinga Newsdesk - Jan 23, 2024, 8:19AM

Thursday, January 04, 2024

Prophase Poised To Ramp Up Growth At Pharmaloz And Nebula Genomics In 2024; Company Announces The Hiring Of Long-Time Industry Veteran Jed Latkin As COO To Help Build And Manage This Growth
Benzinga Newsdesk - Jan 4, 2024, 8:14AM

Friday, November 10, 2023

HC Wainwright & Co. Maintains Buy on ProPhase Labs, Lowers Price Target to $11
Benzinga Newsdesk - Nov 10, 2023, 10:27AM

Thursday, November 09, 2023

ProPhase Labs Q3 EPS $(0.30) Misses $(0.20) Estimate, Sales $8.37M Miss $13.06M Estimate
Benzinga Newsdesk - Nov 9, 2023, 8:01AM
Earnings Scheduled For November 9, 2023
Benzinga Insights - Nov 9, 2023, 6:52AM

Wednesday, November 08, 2023

ProPhase Labs Earnings Preview
Benzinga Insights - Nov 8, 2023, 12:01PM

Tuesday, October 17, 2023

Prophase Labs Inc Says Pharmaloz Plan Is To Build Capacity With A Goal To Attain A Revenue Run-rate Of $60 To $80M By Year-End 2024; Pharmaloz Is Projected To Achieve A Run-Rate Of $15M In Annualized Revenues & Run-Rate Of $3M+ In Gross Profit During Q1
Benzinga Newsdesk - Oct 17, 2023, 8:12AM

Thursday, October 12, 2023

DSS Inc. Issues Letter To Shareholders Providing An Update On Progress So Far This Year And Expectations Going Into The End Of The Year
Happy Mohamed - Oct 12, 2023, 8:28AM

Tuesday, August 29, 2023

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Aug 29, 2023, 2:37PM

Monday, August 28, 2023

Stocks That Hit 52-Week Lows On Monday
Benzinga Insights - Aug 28, 2023, 1:54PM

Monday, August 14, 2023

Stocks That Hit 52-Week Lows On Monday
Benzinga Insights - Aug 14, 2023, 1:48PM
HC Wainwright & Co. Reiterates Buy on ProPhase Labs, Maintains $14 Price Target
Benzinga Newsdesk - Aug 14, 2023, 6:43AM

Friday, August 11, 2023

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Aug 11, 2023, 2:01PM

Thursday, August 10, 2023

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Aug 10, 2023, 1:43PM
ProPhase Labs Q2 EPS $(0.20) Misses $(0.14) Estimate, Sales $13.22M Miss $14.14M Estimate
Benzinga Newsdesk - Aug 10, 2023, 8:01AM
Earnings Scheduled For August 10, 2023
Benzinga Insights - Aug 10, 2023, 6:59AM

Thursday, August 03, 2023

ProPhase Labs Teams Up With Certis Oncology To Accelerate Development Of Novel Linebacker Compound
Benzinga Newsdesk - Aug 3, 2023, 8:14AM

Wednesday, July 26, 2023

DSS, Inc.'s (NYSE American: DSS) Subsidiary Appoints New Chief Investment Officer To Aggressively Develop Mutual Fund Business For Eventual Spinoff
David Willey - Sponsored

Thursday, June 29, 2023

Navidea Biopharmaceuticals Rejects ProPhase Labs Offer To Acquire Certain Assets Of Navidea
Benzinga Newsdesk - Jun 29, 2023, 8:04AM

Monday, June 26, 2023

DSS Inc. Is Spinning Off Its Biotech Subsidiary After Signing A Major Licensing Agreement
David Willey - Sponsored

Friday, June 02, 2023

HC Wainwright & Co. Reiterates Buy on ProPhase Labs, Maintains $14 Price Target
Benzinga Newsdesk - Jun 2, 2023, 6:35AM

Thursday, June 01, 2023

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights - Jun 1, 2023, 5:39PM
ProPhase Labs' Cancer Therapeutic, Linebacker-1, Pre-Clinical Studies With Dana Farber/Harvard Cancer Institute Demonstrate Impressive Utility And Move Into Next Phase Of Testing
Happy Mohamed - Jun 1, 2023, 8:33AM

Friday, May 12, 2023

Analyst Expectations for ProPhase Labs's Future
Benzinga Insights - May 12, 2023, 10:01AM
HC Wainwright & Co. Maintains Buy on ProPhase Labs, Lowers Price Target to $14
Benzinga Newsdesk - May 12, 2023, 9:00AM

Thursday, May 11, 2023

Earnings Scheduled For May 11, 2023
Benzinga Insights - May 11, 2023, 9:58AM
Recap: ProPhase Labs Q1 Earnings
Benzinga Insights - May 11, 2023, 8:11AM
ProPhase Labs Q1 EPS $0.03 Beats $(0.09) Estimate, Sales $19.30M Beat $16.30M Estimate
Benzinga Newsdesk - May 11, 2023, 8:01AM

Wednesday, May 03, 2023

ProPhase Labs Says 'pre-clinical data generated has given PBIO reason to believe that LB-1 will also be very effective as a mono-therapy'
Benzinga Newsdesk - May 3, 2023, 8:43AM

Monday, April 10, 2023

Overview Of Value Stocks In The Healthcare Sector
Benzinga Insights - Apr 10, 2023, 10:43AM

Monday, April 03, 2023

5 Value Stocks To Watch In The Healthcare Sector
Benzinga Insights - Apr 3, 2023, 10:43AM

Tuesday, March 28, 2023

ProPhase Labs FY EPS $1.02 Misses $1.15 Estimate, Sales $122.65M Beat $121.33M Estimate
Benzinga Newsdesk - Mar 28, 2023, 8:04AM
Earnings Scheduled For March 28, 2023
Benzinga Insights - Mar 28, 2023, 6:38AM

Monday, March 27, 2023

ProPhase Labs Earnings Preview
Benzinga Insights - Mar 27, 2023, 12:02PM
Impact Biomedical Preparing A Potential Spinoff — What Does This Mean For Investors Of Holding Company DSS, Inc (NYSE American: DSS)?
Ernest Dela Aglanu - Sponsored

Wednesday, March 15, 2023

ProPhase Labs Announces New $6M Stock Repurchase Program
Bill Haddad - Mar 15, 2023, 8:05AM

Wednesday, March 08, 2023

HC Wainwright & Co. Reiterates Buy on ProPhase Labs, Maintains $15 Price Target
Benzinga Newsdesk - Mar 8, 2023, 6:11AM

Wednesday, March 01, 2023

Prophase Labs Collaboration With mProbe And Dr. Christopher Hartley Of Mayo Clinic For The Continued Development Of Its BE-smart Esophageal Pre-cancer Diagnostic Screening Test
Benzinga Newsdesk - Mar 1, 2023, 8:07AM

Thursday, February 23, 2023

HC Wainwright & Co. Reiterates Buy on ProPhase Labs, Maintains $15 Price Target
Benzinga Newsdesk - Feb 23, 2023, 6:15AM

Wednesday, February 22, 2023

ProPhase Labs Announces Plans To Initiate Clinical Trial Of Equivir, Goal To Launch Commercially In Q4 2023
Happy Mohamed - Feb 22, 2023, 8:10AM

Thursday, February 16, 2023

ProPhase Labs Esophageal Cancer Early Detection Test (BE-smart) Featured in Peer-Reviewed Article in the International Journal of Molecular Science
Benzinga Newsdesk - Feb 16, 2023, 8:17AM

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved